- Divi’s Labs reported a net income of 4.30 billion rupees, missing the estimate of 4.55 billion rupees.
- Revenue came in at 21.18 billion rupees, beating the estimate of 20.9 billion rupees.
- Total costs amounted to 15.93 billion rupees.
- Raw material costs were 8.93 billion rupees.
- Employee benefits expenses totaled 2.92 billion rupees, close to the estimate of 2.93 billion rupees.
- The company reported other income of 790 million rupees.
- Shares of Divi’s Labs rose by 2.1% to 4,991 rupees, with 960,970 shares traded.
- Analyst recommendations: 7 buys, 7 holds, 13 sells.
Divi’s Laboratories on Smartkarma
Analysts on Smartkarma, like Tina Banerjee, are bullish on Divi’s Laboratories (DIVI IN) due to its focus on custom synthesis business for future growth. The company recently announced a long-term supply agreement with an MNC customer, signaling a positive growth trajectory. In Q4FY24, Divi’s Laboratories reported strong performance with double-digit revenue growth and improved profitability. The Custom Synthesis business saw significant expansion, growing by 47% YoY and 38% QoQ to INR12 billion, driven by successful project realizations and new additions to the portfolio. Capacity expansion plans at manufacturing facilities highlight the company’s aggressive growth strategy.
According to the insightful research report by Tina Banerjee on Smartkarma, Divi’s Laboratories is poised for continued double-digit growth, supported by strategic partnerships and operational efficiency. The company’s positive performance in Q4FY24 and its ongoing efforts in the custom synthesis segment have garnered investor confidence in its future prospects. With a bullish sentiment towards Divi’s Laboratories, analysts like Tina Banerjee project sustained growth and value creation in the pharmaceutical sector. This indicates a positive outlook for investors looking at long-term investment opportunities in Divi’s Laboratories.
A look at Divi’s Laboratories Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 5 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Divi’s Laboratories Ltd., a company specializing in manufacturing pharmaceutical products, has garnered a promising long-term outlook based on the Smartkarma Smart Scores. With a solid Dividend score of 4 and top-notch Resilience and Momentum scores of 5 each, the company demonstrates a strong financial position and positive market performance.
Although the company scored lower in Value and Growth with scores of 2 and 3 respectively, the overall outlook remains optimistic due to the robust performance in dividend payouts, resilience to market fluctuations, and sustained positive momentum. Divi’s Laboratories‘ diverse product portfolio and contract research activities further enhance its position for continued growth and success in the pharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
